

## **Screening Protocol For Gadolinium Contrast for MRA and MRI**

### **1) Screening for GFR will be done for patients with any of the following risk factors:**

- Patients with history of renal disorder including acute renal failure and hepatorenal syndrome. Patients currently on dialysis (peritoneal dialysis and hemodialysis) are excluded from requiring renal function tests.
- Patients with history of diabetes mellitus.
- Patients with history of vascular disease
- Patients  $\geq$  60 years of age.
- \*Severe liver disease
- Recent vascular surgery including renal or liver transplantation, arteriovenous graft or revision and acute venous thrombosis.

**Lab data is valid for 60 days for outpatients and for 30 days for inpatients with stable medical status.**

**If lab information is not available and the patient is 60 years of age or older and no other risk factor(s) as above, default to the CKD 3b protocol, 1/2 dose for MRI and up to full dose for MRA.**

**2) Prohance will be available as a backup gadolinium agent for Multihance. Omniscan will be available for pediatric patients less than 2 years of age.** (Of the five gadolinium agents, Multihance and Prohance appear to have the best safety profiles at the present time).

\*overestimates GFR so use 40 ml/min/1.73 m<sup>2</sup> as lower limit of CKD 3b in these patients.